R01 DA003889/DA/NIDA NIH HHS/United States[Grant Number] - Search Results

Year	Number of Results
2006	1
2008	3
2009	4
2010	1
2011	5
2012	7
2013	6
2014	3
2015	4
2016	6
2017	7
2018	9
2019	6
2020	3
2021	3
2022	0

1

Potential Therapeutic Effects of Psilocybin.

Johnson MW, Griffiths RR. Johnson MW, et al. Neurotherapeutics. 2017 Jul;14(3):734-740. doi: 10.1007/s13311-017-0542-y. Neurotherapeutics. 2017. PMID: 28585222 Free PMC article. Review.

2

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.

Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, Cosimano MP, Klinedinst MA. Griffiths RR, et al. J Psychopharmacol. 2016 Dec;30(12):1181-1197. doi: 10.1177/0269881116675513. J Psychopharmacol. 2016. PMID: 27909165 Free PMC article. Clinical Trial.

3

Human hallucinogen research: guidelines for safety.

Johnson M, Richards W, Griffiths R. Johnson M, et al. J Psychopharmacol. 2008 Aug;22(6):603-20. doi: 10.1177/0269881108093587. Epub 2008 Jul 1. J Psychopharmacol. 2008. PMID: 18593734 Free PMC article. Review.

4

Long-term follow-up of psilocybin-facilitated smoking cessation.

Johnson MW, Garcia-Romeu A, Griffiths RR. Johnson MW, et al. Am J Drug Alcohol Abuse. 2017 Jan;43(1):55-60. doi: 10.3109/00952990.2016.1170135. Epub 2016 Jul 21. Am J Drug Alcohol Abuse. 2017. PMID: 27441452 Free PMC article. Clinical Trial.

5

Caffeinated energy drinks--a growing problem.

Reissig CJ, Strain EC, Griffiths RR. Reissig CJ, et al. Drug Alcohol Depend. 2009 Jan 1;99(1-3):1-10. doi: 10.1016/j.drugalcdep.2008.08.001. Epub 2008 Sep 21. Drug Alcohol Depend. 2009. PMID: 18809264 Free PMC article. Review.

6

Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function.

Johnson MW, Hendricks PS, Barrett FS, Griffiths RR. Johnson MW, et al. Pharmacol Ther. 2019 May;197:83-102. doi: 10.1016/j.pharmthera.2018.11.010. Epub 2018 Dec 4. Pharmacol Ther. 2019. PMID: 30521880 Review.

7

The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.

Johnson MW, Griffiths RR, Hendricks PS, Henningfield JE. Johnson MW, et al. Neuropharmacology. 2018 Nov;142:143-166. doi: 10.1016/j.neuropharm.2018.05.012. Epub 2018 Jun 5. Neuropharmacology. 2018. PMID: 29753748 Free PMC article. Review.

8

Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates.

Barrett FS, Griffiths RR. Barrett FS, et al. Curr Top Behav Neurosci. 2018;36:393-430. doi: 10.1007/7854_2017_474. Curr Top Behav Neurosci. 2018. PMID: 28401522 Free PMC article. Review.

9

Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.

Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Johnson MW, et al. J Psychopharmacol. 2014 Nov;28(11):983-92. doi: 10.1177/0269881114548296. Epub 2014 Sep 11. J Psychopharmacol. 2014. PMID: 25213996 Free PMC article. Clinical Trial.

10

Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.

Garcia-Romeu A, Griffiths RR, Johnson MW. Garcia-Romeu A, et al. Curr Drug Abuse Rev. 2014;7(3):157-64. doi: 10.2174/1874473708666150107121331. Curr Drug Abuse Rev. 2014. PMID: 25563443 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results